Table 1.
Clinical characteristics of patients with systemic sclerosis beginning iloprost infusion at our facility between 2004 and 2021.
| Characteristics | n = 113 |
|---|---|
| Female, n (%) | 94 (83.2) |
| BMI, mean ± SD | 24.19 ± 3.94 |
| Age (years), mean ± SD | 49.28 ± 13.57 |
| Current smoker, n (%) | 34 (30.6) |
| Disease duration (years), mean ± SD | 2.28 ± 2.8 |
| Iloprost rate (ng/kg/min), median (IQR) | 0.88 (0.37) |
| mRSS, mean ± SD | 7.4 ± 4.2 |
| Diffuse pattern, n (%) | 42 (37.2) |
| Prior digital ulcers, n (%) | 45 (40) |
| Autoantibodies | |
| Anti-Topo I antibodies, n (%) | 28 (24.8) |
| Anti-centromeric antibodies, n (%) | 50 (44.2) |
| Anti-RNA polymerase III antibodies, n (%) | 6 (5.3) |
| Anti-RNP antibodies, n (%) | 5 (4.4) |
| Anti-SSA antibodies, n (%) | 8 (7.1) |
| Other antibodies, n (%) | 16 (14.1) |
| Major organ involvement | |
| Gastrointestinal manifestation, n (%) | 56 (50) |
| Interstitial lung disease, n (%) | 37 (32.7) |
| Pulmonary artery hypertension, n (%) | 5 (4.4) |
| Myocardial or pericardial involvement, n (%) | 16 (14.1) |
| Ongoing therapies | |
| CCB combination therapy, n (%) | 43 (38.1) |
| Endothelin inhibitors combination therapy, n (%) | 16 (14.2) |
| Immunosuppressants, n (%) | 47 (41.6) |
BMI, body mass index; CCB, calcium channel blocker; ILO, iloprost; IQR, interquartile range; mRSS, modified Rodnan’s skin score; RNP, ribonucleoprotein; SD, standard deviation; SSA, Sjogren’s syndrome–related A; Topo I, topoisomerase I.
Immunosuppressive therapy includes methotrexate, leflunomide, mycophenolate mofetil, rituximab, and tocilizumab.